Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;42(7):663-667.
doi: 10.1002/cac2.12296. Epub 2022 Apr 29.

ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients

Dingxie Liu  1 , Qiongyu Hao  2 , Jieqing Li  2   3 , Qun Li  4 , Kun Wang  3 , Qing Geng  5 , Yutong Wu  1 , Jaydutt V Vadgama  2 , Yong Wu  2
Affiliations

ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients

Dingxie Liu et al. Cancer Commun (Lond). 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, except that Liu has equity interest in Bluewater Biotech LLC.

Figures

FIGURE 1
FIGURE 1
Prediction and validation of biological functions of ZBED2. (A) Heatmap of the Spearman coefficients for the correlations between ZBED2 expression and 27 cancer‐related pathways in five cohorts based on the Affymetrix U133 platform. The pathway activities were computed using BinReg approach as described in Supplementary Methods. Each cell represents one coefficient value. (B) Dot plot showing ZBED2‐related enrichment of hallmark gene sets in GSEA of all the 8 cohorts in this study. Each node dot indicates that the corresponding hallmark gene set is enriched in ER‐negative BC with higher expression of ZBED2 in the corresponding BC cohort. The dot size represents the enrichment degree (shown as the absolute value of NES minus 1.35) of hallmark gene sets. The color intensity of dotes represents the FDR values obtained in GSEA analysis. The 7 gene sets that show enrichment in all of the 8 cohorts were highlighted in rectangle. (C) Effects of ZBED2 on ISG expression induced by IFNγ in two ER‐negative BC cell lines MDA‐MB‐231 and SK‐BR‐3. Cells infected with or without ZBED2 lentivirus were treated with IFNγ for 12 h prior to Western blotting analysis. (D) Upregulation or downregulation of ZBED2 is observed after lentivirus‐transduced overexpression or knockdown using Western blotting analysis. (E) Colony formation of MDA‐MB‐231 and SK‐BR‐3 cells upon overexpression or silence of ZBED2. The cells were recovered in regular media for 10 days, and colonies were counted from more than three experiments. Left panel: A representative result of colony formation of BC cells. Right panel: Bar graph presentation of the colony numbers (mean ± standard deviation) from three experiments. Abbreviations: ALK, anaplastic lymphoma kinase; AR, androgen receptor; BCAT, Wnt/β‐catenin; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GluDep, glucose deprivation; HER2, human epidermal growth factor receptor 2; IFN, interferon; IGF1, insulin like growth factor 1; LacAci, lactic acidosis; NES, normalized enrichment score; PI3K, phosphoinositide 3‐kinases; PR, progesterone receptor; STAT3, signal transducer and activator of transcription 3; TGFβ, transforming growth factor‐β; TNFα, tumor necrosis factor α
See this image and copyright information in PMC

References

    1. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple‐negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98. - PMC - PubMed
    1. Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019;199:30–57. - PubMed
    1. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, et al. Genome and transcriptome sequencing in prospective metastatic triple‐negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12(1):104–16. - PubMed
    1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple‐negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90. - PMC - PubMed
    1. Desmedt C, Haibe‐Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65. - PubMed

Publication types